-
Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria.
Cancer Res. 2010 Nov 1;70(21):8558-68
PMID: 20959471
-
Interleukin-10: new perspectives on an old cytokine.
Immunol Rev. 2008 Dec;226:205-18
PMID: 19161426
-
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein.
Immunity. 2008 Jul 18;29(1):21-32
PMID: 18631454
-
Tumor regulatory T cells potently abrogate antitumor immunity.
J Immunol. 2009 May 15;182(10):6160-7
PMID: 19414769
-
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
J Exp Med. 2005 Oct 3;202(7):919-29
PMID: 16186184
-
Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis.
Carcinogenesis. 2010 Mar;31(3):334-41
PMID: 20028726
-
Regulatory T cells and treatment of cancer.
Curr Opin Immunol. 2008 Apr;20(2):241-6
PMID: 18508251
-
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Nat Med. 2004 Sep;10(9):942-9
PMID: 15322536
-
T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.
J Immunol. 1999 Nov 1;163(9):5020-8
PMID: 10528207
-
HMGB1 is an endogenous immune adjuvant released by necrotic cells.
EMBO Rep. 2004 Aug;5(8):825-30
PMID: 15272298
-
HMGB1: a two-headed signal regulating tumor progression and immunity.
Curr Opin Immunol. 2008 Oct;20(5):518-23
PMID: 18599281
-
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54
PMID: 17671115
-
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.
Neoplasia. 2009 Jul;11(7):615-28
PMID: 19568407
-
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.
Immunol Rev. 2006 Aug;212:28-50
PMID: 16903904
-
Altered immune responses in interleukin 10 transgenic mice.
J Exp Med. 1997 Jun 16;185(12):2101-10
PMID: 9182682
-
HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
PLoS Med. 2009 Jan 13;6(1):e10
PMID: 19143470
-
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.
J Immunol. 2008 Sep 15;181(6):4363-70
PMID: 18768895
-
The regulation of IL-10 production by immune cells.
Nat Rev Immunol. 2010 Mar;10(3):170-81
PMID: 20154735
-
Interleukin-10 and the immune response against cancer: a counterpoint.
J Leukoc Biol. 2005 Nov;78(5):1043-51
PMID: 16204623
-
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74
PMID: 21376230
-
Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis.
Int J Oncol. 2009 Feb;34(2):425-31
PMID: 19148477
-
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
Nature. 2000 May 18;405(6784):354-60
PMID: 10830965
-
High-mobility group box 1 and cancer.
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40
PMID: 20123075
-
Myeloid-derived suppressor cells as regulators of the immune system.
Nat Rev Immunol. 2009 Mar;9(3):162-74
PMID: 19197294
-
Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
Mol Ther. 2005 Jun;11(6):941-9
PMID: 15922965
-
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.
J Immunol. 2007 Mar 1;178(5):2883-92
PMID: 17312132
-
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.
Nat Immunol. 2008 Mar;9(3):239-44
PMID: 18285775
-
DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity.
J Immunol. 2011 Mar 15;186(6):3517-26
PMID: 21300822
-
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
J Clin Invest. 2007 Sep;117(9):2570-82
PMID: 17710230
-
Masquerader: high mobility group box-1 and cancer.
Clin Cancer Res. 2007 May 15;13(10):2836-48
PMID: 17504981
-
Strategies for use of IL-10 or its antagonists in human disease.
Immunol Rev. 2008 Jun;223:114-31
PMID: 18613832
-
The effect of high-mobility group box 1 protein on activity of regulatory T cells after thermal injury in rats.
Shock. 2009 Mar;31(3):322-9
PMID: 18665051
-
The cytokine activity of HMGB1.
J Leukoc Biol. 2005 Jul;78(1):1-8
PMID: 15734795
-
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.
Cancer Res. 2011 May 15;71(10):3505-15
PMID: 21444674
-
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Nat Med. 2007 Sep;13(9):1050-9
PMID: 17704786
-
Mechanisms of foxp3+ T regulatory cell-mediated suppression.
Immunity. 2009 May;30(5):636-45
PMID: 19464986
-
Endogenous HMGB1 regulates autophagy.
J Cell Biol. 2010 Sep 6;190(5):881-92
PMID: 20819940
-
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.
Blood. 2008 Jan 1;111(1):219-28
PMID: 17885078
-
Regulatory T cells, tumour immunity and immunotherapy.
Nat Rev Immunol. 2006 Apr;6(4):295-307
PMID: 16557261
-
HMGB1 and RAGE in inflammation and cancer.
Annu Rev Immunol. 2010;28:367-88
PMID: 20192808
-
Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer.
Pathobiology. 2009;76(4):155-62
PMID: 19571604
-
Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
Cancer Immunol Immunother. 2007 Jan;56(1):48-59
PMID: 16612596
-
HMGB1: guiding immunity from within.
Trends Immunol. 2005 Jul;26(7):381-7
PMID: 15978523
-
High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.
Immunol Rev. 2007 Dec;220:35-46
PMID: 17979838